While innovative medical technology is transforming America’s healthcare system, only 10-20% of patients who could benefit from innovative products and therapies actually receive them. This is due to either lack of coverage or slow, unresponsive and uncoordinated coverage, coding and reimbursement decisions by Medicare and a myriad of other payer organizations. This results in significant delays in the bench to bedside cycle and poor return-on-investment.

In today’s evolving biomedical market, one thing seems clear: top scientists and secure funding are not enough. Companies have to be successful in order to maintain top talent and generate continuous revenue. Success demands new criteria. As Medicare is increasingly scrutinizing costs, the need for effective and proactive regulatory and reimbursement strategies, economic analyses, and consideration of third party coverage are crucial to determine timelines and significant revenues.

The following are our key areas of expertise:

      • Clinical Studies & Economics
            Analysis of Medicare Data & Hospital Claims
            Outcomes Analysis
            Cost & Benefit Models
      • Reimbursement Strategy & Execution
            Coverage
            Payment
            New Codes
            Technology Assessment
            Economic Research
      • Marketing & Research
            Competitive Analysis
            Quantitative Marketing